Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Current Leases (2021 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Current Leases for 5 consecutive years, with $5.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 11.86% to $5.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.7 million, a 11.86% increase, with the full-year FY2024 number at $5.6 million, up 79.01% from a year prior.
  • Current Leases was $5.7 million for Q3 2025 at 4D Molecular Therapeutics, roughly flat from $5.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $5.7 million in Q2 2025 to a low of $1.2 million in Q4 2021.
  • A 5-year average of $3.6 million and a median of $3.1 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: skyrocketed 115.68% in 2022, then rose 3.0% in 2024.
  • 4D Molecular Therapeutics' Current Leases stood at $1.2 million in 2021, then soared by 115.68% to $2.7 million in 2022, then grew by 18.61% to $3.1 million in 2023, then surged by 79.01% to $5.6 million in 2024, then increased by 1.03% to $5.7 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Current Leases are $5.7 million (Q3 2025), $5.7 million (Q2 2025), and $5.7 million (Q1 2025).